Autism spectrum disorders: Pharmacotherapy for challenging behaviors

Journal of Developmental and Physical Disabilities

Volumn 20, Issue 2, 2008, Pages 175-191

  Matson, Johnny L ^a   Dempsey, Timothy ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Autism spectrum disorders; Challenging behaviors; Pharmacotherapy

Indexed keywords

EID: 40249108321     PISSN: 1056263X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10882-007-9088-y     Document Type: Article

References (137)

1. Adetunji, B., Matthews, M., Osinowo, T., & Williams, A. (2006). Risperidone for the core symptom domains of autism. American Journal of Psychiatry, 163, 551.
2. Aman, M. G., & Langworthy, K. S. (2000). Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30, 451-459.
3. Aman, M. G., van Bourgondien, M. E., Wolford, P. L., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.
4. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders, text revision (4th ed.). Washington, DC: American Psychiatric Association.
5. Anderson, L. T., Campbell, M., Adams, P., Small, A. M., Perry, R., & Shell, J. (1989). The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. Journal of Autism and Developmental Disorders, 19, 227-239.
6. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. T. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195-1202.
7. Arnold, L. E., Vitiello, B., McDougle, C., Scahill, L., Bhavik, S., Nilda, G., et al. (2003). Parent-defined target symptoms respond to risperidone in RVPP autism study: Customer approach to clinical trials. Journal of American Academy of Child and Adolescent Psychiatry, 42, 1443-1450.
8. Barbaresi, W. J., Katusic, S. K., & Voight, R. G. (2006). Autism: A review of the state of the science for pediatric primary health care clinicians. Archives of Pediatric and Adolescent Medicine, 160, 1167-1175.
9. Bardenstein, R., Chez, M., Helfaud, B., Buchanan, S. P., & Zucker, M. (1998). Improvement in EEG and clinical function in pervasive developmental delay (PDD): Effect of valproic acid. Annals of Neurology, 50(4), (Supplement), 86.
10. Barnard, L., Young, A. H., Pearson, J., Geddes, J., & O'Brien, G. (2002). A systematic review of the use of atypical antipsychotics in autism. Journal of Psychopharmacology, 16, 93-101.
11. Belsito, K. M., Law, P. A., Kirk, K. S., Landa, R. J., & Zimmerman, A. W. (2001). Lamotrigine therapy for autistic disorder: A randomized, double-blind placebo-controlled trial. Journal of Autism and Developmental Disorders, 31, 175-181.
12. Ben-Itzchak, E., & Zachor, D. A. (2007). The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Research in Developmental Disabilities, 28, 287-303.
13. Boon-Yasidhi, V., Tarugsa, J., Suwanwattana, C., & Soising, L. (2002). Risperidone in the treatment of autistic Thai children under 4 years of age. Journal of the Medical Association of Thailand, 85(Supplement 2), 5784-5789.
14. Broadstock, M., & Doughty, C. (2003). The effectiveness of pharmacological therapies for young people and adults with Autism Spectrum Disorder (ASD). New Zealand Health Technology Assessment (NZHTA) Report 2003 6(1).
15. Bryson, S. E., Rogers, S. J., & Fombonne, E. (2003). Autism spectrum disorders: Early detection, intervention, education and psychopharmacological management. Canadian Journal of Psychiatry, 48, 506-516.
16. Canella, H. I., O'Reilly, M. F., & Lancioni, G. E. (2006). Treatment of hand mouthing in individuals with severe to profound developmental disabilities: A review of the literature. Research in Developmental Disabilities, 27, 529-544.
17. Chavez, B., Chavez-Brown, M., & Rey, J. A. (2006). Role of risperidone in children with autism spectrum disorders. The Annals of Pharmacotherapy, 40, 909-916.
18. Chen, N. C., Bedair, H. S., McKay, B., Bowers, M. B., & Mazure, C. (2001). Clozapine in the treatment of aggression in an adolescent with autistic disorder. Journal of Clinical Psychiatry, 62, 479-480.
19. Chez, M. G., Memon, S., & Hung, P. C. (2004). Neurologic treatment strategies in autism: An overview of medical intervention strategies. Seminars in Pediatric Neurology, 11, 229-235.
20. Chung, M. C., Cumella, S., Bickerton, W. L., & Winchester, C. (2003). The prevalence of aggressive behaviors in the hospital, the family and the communitarian residences. The European Journal of Psychiatry, 17, 1-14.
21. Coghill, D. (2002). Evidence-based psychopharmacology for children and adolescents. Current Opinion in Psychiatry, 15, 361-368.
22. Coghill, D. (2003). Current issues in child and adolescent psychopharmacology. Part 2: Anxiety and obsessive-compulsive disorders, autism, Tourette's and schizophrenia. Advances in Psychiatric Treatment, 9, 289-299.
23. Cook, E. H., Rowlett, R., Jaselskis, C., & Leventhal, B. L. (1992). Fluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 739-745.
24. DeLong, G. R., Teague, L. A., & McSwain-Kamran, M. (1998). Effects of fluoxetine treatment in young children with idiopathic autism. Developmental Medicine and Child Neurology, 4, 551-562.
25. DiMartino, A., & Tuchman, R. F. (2001). Antiepileptic drugs: Affective use in autism spectrum disorders. Pediatric Neurology, 25, 199-207.
26. Dinca, O., Paul, M., & Spencer, N. J. (2005). Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders. Journal of Psychopharmacology, 19, 521-532.
27. Dominick, K. C., Davis, N. O., Lainhart, J., Tager-Flusberg, H., & Folstein, S. (2007). Atypical behavior in children with autism and children with a history of language impairment. Research in Developmental Disabilities, 28, 145-162.
28. Edelson, M. G. (2006). Are the majority of children with autism mentally retarded. Focus on Autism and Other Developmental Disabilities, 21, 66-83.
29. Ellis, E. M., Ala'i-Rosales, S. S., Glenn, S. S., Rosales-Ruiz, J., & Greenspoon, J. (2006). The effects of graduated exposure, modeling, and contingent social attention on tolerance to skin care products with two children with autism. Research in Developmental Disabilities, 27, 585-598.
30. Fatemi, S. H., Realmuto, G. M., Khan, L., & Thuras, P. (1998). Fluoxetine in treatment of adolescent patients with autism: A longitudinal open trial. Journal of Autism and Developmental Disorders, 28, 303-307.
31. Feroz-Nainar, C., & Roy, M. (2006). Risperidone and late onset tics. Autism, 10, 679-685.
32. Filipek, P. A., Steinberg-Epstein, R., & Book, T. M. (2006). Interventions for autism spectrum disorders. The Journal of the American Society for Experimental NeuroTherapeutics, 3, 207-216.
33. Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., The Risperidone Disruptive Behavior Study Group (2004). Long-term, open-label study of Risperidone in children with severe disruptive behavior and below average I.Q. American Journal of Psychiatry, 161, 677-684.
34. Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E., & Blumer, J. L. (2000). A double-blind pilot study of risperidone in the treatment of conduct disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 39, 509-516.
35. Fishman, S., & Steele, M. (1996). Use of risperidone in pervasive developmental disorders: A case series. Journal of Child and Adolescent Psychopharmacology, 6, 177-190.
36. Folstein, S., & Santangelo, S. (2000). Does Asperger syndrome aggregate in families? In A. Klin, F. R. Volkmar, & S. Sparrow (Eds.), Asperger syndrome (pp. 159-171). New York: Guilford.
37. Fombonne, E. (1999). The epidemiology of autism: A review. Psychological Medicine, 29, 726-728.
38. Fombonne, E. (2006). Risperidone improves restricted, repetitive and stereotyped behaviors in autistic children and adolescents. Evidence Based Mental Health, 9, 6.
39. Fountoulakis, K. N., Nimatoudis, I., Iacovides, A., & Kaprinis, G. (2004). Off-label indications for atypical antipsychotics: A systematic review. Annals of General Hospital Psychiatry, 3, 1-10.
40. Gagliano, A., Germano, E., Pastorino, G., Impallomeni, C., D'Arrigo, C., Calamoneri, F., et al. (2004). Risperidone treatment of children with autistic disorder: Effectiveness, tolerability and pharmacokinetic implications. Journal of Child and Adolescent Psychopharmacology, 14, 39-47.
41. Gerlai, R., & Gerlai, J. (2004). Autism: A target of pharmacotherapies? Drug Discovery Today, 9, 366-374.
42. Goin-Kochel, R. P., Myers, B. J., & Mackintosh, V. H. (2007). Parental reports on the use of treatments and therapies for children with autism spectrum disorders. Research in Autism Spectrum Disorders, 10, 439-451.
43. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry, 149, 363-366.
44. Gordon, C. T., State, R. C., Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441-447.
45. Green, V. A., Pituch, K. A., Itchon, J., Choi, A., O'Reilly, M., & Sigafoos, J. (2006). Internet survey of treatments used by parents of children with autism. Research in Developmental Disabilities, 27, 70-84.
46. Handen, B. L., & Lubetsky, M. (2005). Pharmacotherapy in autism and related disorders. School Psychology Quarterly, 20, 155-171.
47. Hardan, A., Johnson, K., Johnson, C., & Hrecznyj, B. (1996). Case study: Risperidone treatment of children and adolescents with developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1551-1556.
48. Hellings, J. A., Kelley, L. A., Gabrielli, W. F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57, 333-336.
49. Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229-238.
50. Herrington, J. D., Baron-Cohen, S., Wheelwright, S. J., Singh, K. D., Bullmore, E. T., Brammer, M., et al. (2007). The role of MT+VS during biological motion perception in Asperger syndrome: An fMRI study. Research in Autism Spectrum Disorders, 1, 14-27.
51. Hill, J., & Furniss, F. (2006). Patterns of emotional and behavioural disturbance associated with autistic traits in young people with severe intellectual disabilities and challenging behaviours. Research in Developmental Disabilities, 27, 517-528.
52. Hilton, C., Graver, K., & LaVesser, P. (2007). Relationship between social competence and sensory processing in children with high functioning autism spectrum disorders. Research in Autism Spectrum Disorders, 1, 164-173.
53. Hoch, J., & Symons, F. J. (2007). Matching analysis of socially appropriate and destructive behavior in developmental disabilities. Research in Developmental Disabilities, 28, 238-248.
54. Holden, B., & Gitlesen, J. P. (2006). A total population study of challenging behaviour in the country of Hedmark, Norway: Prevalence and risk markers. Research in Developmental Disabilities, 27, 456-465.
55. Hollander, E., Kaplan, A., Cartwright, C., & Reichman, D. (2000). Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: An open retrospective clinical report. Journal of Child Neurology, 15, 132-135.
56. Hughes, D. M. (2002). Risperidone in children and adolescents with autistic disorder and aggressive behaviour. British Journal of Developmental Disabilities, 48, 113-122.
57. Hunsinger, D. M., Nguyen, T., Zebraski, S. E., & Raffa, R. B. (2000). Is there a basic for novel pharmacotherapy in autism? Life Sciences, 67, 1667-1682.
58. Ingersoll, B., & Gergans, S. (2007). The effect of a parent-implemented imitation intervention on spontaneous imitation skills in young children with autism. Research in Developmental Disabilities, 28, 163-175.
59. Järbrink, K., McCrone, P., Fombonne, E., Zandén, H., & Knapp, M. (2007). Cost-impact of young adults with high-functioning autism spectrum disorders. Research in Developmental Disabilities, 28, 94-104.
60. Kabot, S., Masi, W., & Segal, M. (2003). Advances in the diagnosis and treatment of autism spectrum disorders. Professional Psychology: Research and Practice, 34, 26-33.
61. Kemner, C., van Engeland, H., & Tuynman-Qua, H. (2000). An open-label study of olanzapine in children with PDD. Schizophrenia Research, 41, 194.
62. Kerbeshian, J., Burd, L., & Avery, K. (2001). Pharmacotherapy of autism: A review and clinical approach. Journal of Developmental and Physical Disabilities, 13, 199-228.
63. Kern, J. K., Garver, C. R., Grannemann, B. D., Trivedi, M. H., Carmody, T., Andrews, A. A., et al. (2007). Response to vestibular sensory events in autism. Research in Autism Spectrum Disorders, 1, 67-74.
64. King, B. H. (2000). Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30, 439-445.
65. King, B. H., & Bostic, J. Q. (2006). An update on pharmacologic treatments for autism spectrum disorder. Child and Adolescent Psychiatry Clinics of North America, 15, 161-175.
66. Koshes, R. J. (1997). Use of fluoxetine for obsessive-compulsive behavior in adults with autism. American Journal of Psychiatry, 154, 578.
67. Kwok, H. W. M. (2003). Psychopharmacology in autism spectrum disorders. Current Opinion in Psychiatry, 16, 529-534.
68. Lam, K. S. L., Aman, M. G., & Arnold, L. E. (2006). Neurochemical correlates of autistic disorder: A review of the literature. Research in Developmental Disabilities, 27, 254-289.
69. Laud, R. B., & Matson, J. L. (2006). The relationship between manic symptoms on the DASH-II and YMRS and feeding/mealtime behavior problems. Research in Developmental Disabilities, 27, 559-566.
70. Levy, S. E., & Hyman, S. L. (2005). Novel treatments for autistic spectrum disorders. Mental Retardation and Developmental Disabilities Research Reviews, 11, 131-142.
71. Lewis, F. M., Murdoch, B. E., & Woodyatt, G. C. (2007). Linguistic abilities in children with autism spectrum disorders. Research in Autism Spectrum Disorders, 1, 85-100.
72. MacDonald, R., Green, G., Mansfield, R., Geckeler, A., Gardenier, N., Anderson, J., et al. (2007). Stereotypy in young children with autism and typically developing children. Research in Developmental Disabilities, 28, 266-277.
73. Machalicek, W., O'Reilly, M. F., Beretvas, N., Sigafoos, J., & Lancioni, G. E. (2007). A review of interventions to reduce challenging behavior in school settings for students with autism spectrum disorders. Research in Autism Spectrum Disorders, 1, 229-246.
74. Magnusson, P., & Saemundsen, E. (2001). Prevalence of autism in Iceland. Journal of Autism and Developmental Disorders, 31, 153-163.
75. Malone, R. P., Cater, J., Sheikh, R. M., Choudhury, M. S., & Delaney, M. A. (2001). Olanzapine versus haloperidol in children with autistic disorder: An open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 887-894.
76. Malone, R. P., Ernst, M., Godfrey, K. A., Locascio, J. J., & Campbell, M. (1991). Repeated episodes of neuroleptic-related dyskinesias in autistic children. Psychopharmacology Bulletin, 27, 113-117.
77. Martin, A., Koenig, K., Anderson, G. M., & Scahill, L. (2003). Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. Journal of Autism and Developmental Disorders, 33, 77-85.
78. Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9, 99-107.
79. Masi, G. (2001). Risperidone monotherapy in preschool children with pervasive developmental disorders. Journal of Child Neurology, 16, 395-400.
80. Masi, G., Cosenza, A., & Mucci, M. (2001b). Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. Journal of Child and Adolescent Psychopharmacology, 11, 389-394.
81. Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2001). Open trial of risperidone in 24 young children with pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1206-1214.
82. Masi, G., Cosenza, A., Mucci, M., & Brovedani, P. (2003). A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. Journal of Clinical Psychiatry, 64, 1039-1047.
83. Matson, J. L. (2007a). Current status of differential diagnosis for children with autism spectrum disorders. Research in Developmental Disabilities, 28, 109-118.
84. Matson, J. L. (2007b). Determining treatment outcome in early intervention programs for autism spectrum disorders: A critical analysis of measurement issues in learning based interventions. Research in Developmental Disabilities, 28, 207-218.
85. Matson, J. L., Cooper, C., Malone, C. J., & Moskow, S. L. (2007a). The relationship of self-injurious behavior and other maladaptive behaviors among individuals with severe and profound intellectual disability. Research in Developmental Disabilities (in press). DOI 10.10161j.ridd.2007.02.001.
86. Matson, J. L., González, M. L., Smith, K. R., Terlonge, C., Thorson, R. T., & Dixon, D. R. (2006). Assessing side effects of pharmacotherapy treatment of bipolar disorder: A 20-year review of the literature. Research in Developmental Disabilities, 27, 467-500.
87. Matson, J. L., & LoVullo, S. V. (2007). A review of the behavioral treatments for self-injurious behavior (SIB) of persons with autism spectrum disorders. Behavior Modification (in press).
88. Matson, J. L., & Minshawi, N. F. (2006). Early intervention for autism spectrum disorders. A critical analysis. Oxford, Engalnd: Elsevier.
89. Matson, J. L., & Nebel-Schwalm, M. S. (2007). Comorbid psychopathology with autism spectrum disorders in children: An overview. Research in Developmental Disabilities, 28, 341-352.
90. Matson, J. L., Nebel-Schwalm, M., & Matson, M. L. (2007b). A review of methodological issues in the differential diagnosis of autism spectrum disorders in children. Research in Autism Spectrum Disorders, 1, 38-54.
91. Matson, J. L., & Wilkins, J. (2007). A critical review of assessment targets and methods for social skills excesses and deficits for children with autism spectrum disorders. Research in Autism Spectrum Disorders, 1, 28-37.
92. McCracken, J. T., McDougle, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002a). Risperidone in children with serious behavioral problems. The New England Journal of Medicine, 347, 314-321.
93. McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., et al. (2002b). Risperidone in children with autism and serious behavioral problems: Research units on pediatric psychopharmacology autism network. New England Journal of Medicine, 347, 314-321.
94. McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H. (1998). Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Clinical Psychopharmacology, 18, 62-66.
95. McDougle, C. J., Holmes, J. P., & Bronson, M. R. (1997). Risperidone treatment of children and adolescents with pervasive developmental disorders: A prospective open-label study. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 685-693.
96. McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998b). A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Archives of General Psychiatry, 55, 633-641.
97. McDougle, C. J., Kem, D. L., & Posey, D. J. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 921-927.
98. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptoms of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry, 162, 1142-1148.
99. McDougle, C. J., Stigler, K. A., Erickson, C. A., & Posey, D. J. (2006). Pharmacology in autism. Clinical Neuroscience Research, 6, 179-188.
100. Metz, B., Mulick, J. A., & Butter, E. M. (2005). Autism: A late 20th century fad magnet. In J. W. Jacobson, R. M. Foxx, & J. A. Mulick (Eds.). Controversial therapies for developmental disabilities. Mahwah, NJ: Lawrence Erlbaum.
101. Moran, R. W., & Gibbons, P. (2001). Intra-examiner and inter-examiner reliability for palpation of the cranial rhythmic impulse at the head and sacrum. Journal of Manipulative Physiological Therapy, 24, 183-190.
102. Morgan, S., & Taylor, E. (2007). Antipsychotic drugs in children with autism. British Medical Journal, 334, 1069-1070.
103. Nicholson, J., Konstantinidi, E., & Furniss, F. (2006). On some psychometric properties of the questions about behavioral function (QABF) scale. Research in Developmental Disabilities, 27, 337-352.
104. Nicolson, R., Awad, G., & Sloman, L. (1998). An open trial of risperidone in young autistic children. Journal of the American Academy of Child and Adolescent Psychiatry, 37, 372-376.
105. Palmero, M. T., & Curatolo, P. (2004). Pharmacologic treatment in autism. Journal of Child Neurology, 19, 155-164.
106. Perry, R., Pataki, C., Munoz-Silva, D. M., Armenteros, R. R., & Silva, R. R. (1997). Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. Journal of Child and Adolescent Psychopharmacology, 7, 167-179.
107. Plioplys, A. V. (1994). Autism: Electroencephalogram abnormalities and clinical improvement with valproic acid. Archives of Pediatric and Adolescent Medicine, 148, 220-222.
108. Posey, D. J., Kem, D. L., Swiezy, N. B., Sweeten, T. L., Wiegand, R. E., & McDougle, C. J. (2004). A pilot study of d-cycloserine in subjects with autistic disorder. American Journal of Psychiatry, 161, 2115-2117.
109. Posey, D. J., & McDougle, C. J. (2000). The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Review of Psychiatry, 8, 45-63.
110. Posey, D. J., Walsh, K. H., Wilson, G. A., & McDougle, C. J. (1999). Risperidone in the treatment of two very young children with autism. Journal of Child and Adolescent Psychopharmacology, 9, 273-276.
111. Potenza, M. N., Holmes, J. P., Kanes, S. J., & McDougle, C. (1999). Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: An open-label pilot study. Journal of Clinical Psychopharmacology, 19, 37-44.
112. Poustka, L., & Poustka, F. (2007). Psychopharmakologie autistischer störungen. Kinder-und Jugend-psychiatrie und Psychotherapie, 35, 87-94.
113. Research Units on Pediatric Psychopharmacology, Aut (2005). Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. American Journal of Psychiatry, 162, 1361-1369.
114. Rojahn, J., Matson, J. L., Lott, D., Esbensen, A., & Smalls, Y. (2001). The Behavior Problem Inventory: An instrument for the assessment of self-injury, stereotyped behavior, and aggression/destruction in individuals with developmental disabilities. Journal of Autism and Developmental Disorders, 31, 558-577.
115. Rutter, M. (1968). Concepts of autism: A review of research. Journal of Child Psychology and Psychiatry, 9, 1-25.
116. Sandler, L., Valiquette, G., Munarriz, R., Bennett, L., Goldstein, I., Scahill, L., et al., the Research Unit on Pediatric Psychopharmacology (2002). Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 1890-1891.
117. Schlosser, R. W., & Sigafoos, J. (2006). Augmentative and alternative communication interventions for persons with developmental disabilities: Narrative review of comparative single-subject experimental studies. Research in Developmental Disabilities, 27, 1-29.
118. Shattock, P., & Whitely, P. (2002). Biochemical aspects in autism spectrum disorders: Updating the opiod-excess theory and presenting new opportunities for biomedical intervention. Expert Opinion Therapy Targets, 6, 175-183.
119. Siklos, S., & Kerus, K. A. (2007). Assessing the diagnostic experiences of a small sample of parents of children with autism spectrum disorders. Research in Developmental Disabilities, 28, 9-22.
120. Singh, N. N., Lancioni, G. E., Winton, A. S. W., Curtis, W. J., Wahler, R. G., Sabaawi, M., et al. (2006). Mindful staff increase learning and reduce aggression in adults with developmental disabilities. Research in Developmental Disabilities, 27, 545-558.
121. Sinha, Y., Silove, N., Wheeler, D., & Williams, K. (2004). Auditory integration training and other sound therapies for autism spectrum disorders. The Cochrane Database of Systematic Reviews, 1, CD003681, pub2.
122. Sokolski, K. N. (2004). Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series. Journal of Child and Adolescent Psychopharmacology, 14, 143-147.
123. Stachnik, J. M., & Nunn-Thompson, C. (2007). Use of atypical antipsychotics in the treatment of autistic disorder. The Annals of Pharmacotherapy, 41, 626-634.
124. Steingard, R. J., Zimnitzky, B., DeMaso, D. R., Bauman, M. L., & Bucci, J. P. (1997). Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7, 9-15.
125. Sweeney, P. P., Forness, S. R., & Levitt, J. G. (1998). An overview of medications commonly used to treat behavioral disorders associated with autism, Tourette syndrome, and pervasive developmental disorders. Focus on Autism and other Developmental Disabilities, 13, 144-150.
126. Symes, M. D., Remington, B., Brown, T., & Hastings, R. P. (2006). Early intensive behavioral intervention for children with autism: Therapists' perspectives on achieving procedural fidelity. Research in Developmental Disabilities, 27, 30-42.
127. Tager-Flusberg, H. (1996). Current theory and research on language and communication in autism. Journal of Autism and Developmental Disorders, 26, 169-172.
128. Tager-Flusberg, H., Joseph, R., & Folstein, S. (2001). Current directions in research on autism. Mental Retardation and Developmental Disabilities Research Reviews, 7, 21-29.
129. Towbin, K. E. (2003). Strategies for pharmacologic treatment of high functioning autism and Asperger syndrome. Child and Adolescent Psychiatric Clinics of North America, 12, 23-45.
130. Tsai, L. Y. (1996). Brief report: Comorbid psychiatric disorders of autistic disorder. Journal of Autism and Developmental Disorders, 26, 159-163.
131. Tsai, L. Y. (1999). Psychopharmacology in autism. Psychosomatic Medicine, 61, 651-665.
132. Tsai, S. J. (2006). Lithium and antidepressants: Potential agents for the treatment of Rett syndrome. Medical Hypotheses, 67, 626-629.
133. Van Lang, N. D. J., Bouma, A., Sytema, S., Kraijer, D. W., & Minderra, R. B. (2006). A comparison of central coherence skills between adolescents with an intellectual disability with and without comorbid autism spectrum disorder. Research in Developmental Disabilities, 27, 217-226.
134. Whittingham, K., Sofronoff, K., & Sheffield, J. K. (2006). Stepping stones triple P: A pilot study to evaluate acceptability of the program by parents of a child diagnosed with an autism spectrum disorder. Research in Developmental Disabilities, 27, 364-380.
135. Zachor, D. A., Roberts, A. W., Hodgens, J. B., Isaacs, J. S., & Merrick, J. (2006). Effects of long-term psychostimulant medication on growth of children with ADHD. Research in Developmental Disabilities, 27, 162-174.
136. Zuddas, A., Di Martino, A., Muglia, P., & Cianchetti, C. (2000). Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability, and discontinuation. Journal of Child and Adolescent Psychopharmacology, 10, 79-90.
137. Zuddas, A., Ledda, M. G., Fratta, A., Muglia, P., & Cianchetti, C. (1996). Clinical effects of clozapine on autistic disorder. American Journal of Psychiatry, 153, 738.